SLE in 2011: Deciphering the role of NETs and networks in SLE.
From neutrophil extracellular traps to genetic networks that underlie the disease and new targeted therapies, important advances in 2011 improve our understanding of the pathogenesis of systemic lupus erythematosus and mark the beginning of our ability to treat it effectively.
Department of Medicine, Rheumatology and Clinical Immunology, Charite Center 12, Charite Universitätsmedizin Berlin and Deutsches Rheumaforschungszentrum, Chariteplatz 01, 10098 Berlin, Germany. thomas.doerner@charite.de
Thomas
T
Dörner
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D005110:Extracellular Space / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000235:genetics / Q000276:immunology / Q000628:therapy; D058990:Molecular Targeted Therapy / Q000379:methods*; D009504:Neutrophils / Q000187:drug effects / Q000276:immunology*; D010587:Phagocytosis / Q000502:physiology
D000911:Antibodies, Monoclonal